DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Blackstone - 1 Anthos - 1 Bayer - 1 Eliquis - 1 David Carnevali - 1 Leslie Adler - 1
Top related locs:
New York City U.S Cambridge , Massachusetts Anthos Bristol German New York
Top related orgs:
Blackstone Group - 1 REUTERS - 1 Blackstone Inc - 1 Anthos Therapeutics - 1 Novartis AG - 1 Novartis - 1 Myers Squibb - 1 Alnylam Pharmaceuticals - 1

Search resuls for: "Anthos Therapeutics"


2 mentions found


☆ Blackstone explores sale of Anthos Therapeutics -sources
  + stars: | 2023-12-04 | by ( David Carnevali | ) www.reuters.com   time to read: +2 min
Signage is seen outside the Blackstone Group headquarters in New York City, U.S., January 18, 2023. Anthos, which does not generate any revenue because its products have not yet hit the market, could be worth several billion dollars in a potential sale, significantly more than the $250 million that Blackstone invested when it founded Anthos in 2019, the sources said. The company's anticoagulants have made significant progress in late-stage clinical trials, the sources added. Blackstone is working with investment bankers to explore a sale of Anthos, the sources said, cautioning that no deal is certain and requesting anonymity because the matter is confidential. Anthos has licensed from Novartis an antibody used in the development of its blood thinners and granted it a minority stake.
Persons: Blackstone, Anthos, Bayer, Eliquis, David Carnevali, Leslie Adler Organizations: Blackstone Group, REUTERS, Blackstone Inc, Anthos Therapeutics, Novartis AG, Novartis, Myers Squibb, Alnylam Pharmaceuticals, Thomson Locations: New York City, U.S, Cambridge , Massachusetts, Anthos, Bristol, German, New York
☆ Bayer flags new blood thinner as $5 bln-plus opportunity
  + stars: | 2023-01-10 | by ( Ludwig Burger Patricia Weiss | Ludwig Burger | Patricia Weiss | ) www.reuters.com   time to read: +3 min
Both are legacy issues from Monsanto, which Bayer acquired for more than $60 billion in 2018. Another activist, Elliott, took a 1.1 billion euro stake in Bayer in 2019 but has kept a low profile. The next-generation blood thinner is one of four new drug hopefuls that Bayer said on Tuesday had combined peak sales potential of more than 12 billion euros. That included an improved outlook for kidney drug Kerendia, with potential annual sales now seen at more than 3 billion euros. ($1 = 0.9313 euros)Reporting by Ludwig Burger and Patricia Weiss Editing by Mark PotterOur Standards: The Thomson Reuters Trust Principles.
0 next >>
Total: 2